vs
Side-by-side financial comparison of BANCFIRST CORP (BANF) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
BANCFIRST CORP is the larger business by last-quarter revenue ($181.0M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 11.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 9.5%).
BancFirst Corporation is an Oklahoma-based financial services holding company. The company operates three subsidiary banks, BancFirst, an Oklahoma state-chartered bank; and Pegasus Bank and Worthington Bank, both Texas state-chartered banks.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
BANF vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $181.0M | $168.4M |
| Net Profit | $59.5M | — |
| Gross Margin | — | — |
| Operating Margin | 41.6% | 50.6% |
| Net Margin | 32.9% | — |
| Revenue YoY | 11.1% | 143.7% |
| Net Profit YoY | 5.3% | — |
| EPS (diluted) | $1.75 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $181.0M | $168.4M | ||
| Q3 25 | $175.5M | $87.3M | ||
| Q2 25 | $169.3M | $82.4M | ||
| Q1 25 | $164.8M | $65.0M | ||
| Q4 24 | $162.9M | $69.1M | ||
| Q3 24 | $163.7M | $51.6M | ||
| Q2 24 | $153.8M | $73.8M | ||
| Q1 24 | $151.0M | $137.7M |
| Q4 25 | $59.5M | — | ||
| Q3 25 | $62.7M | $-31.3M | ||
| Q2 25 | $62.3M | $-12.7M | ||
| Q1 25 | $56.1M | $-40.5M | ||
| Q4 24 | $56.5M | — | ||
| Q3 24 | $58.9M | $-29.5M | ||
| Q2 24 | $50.6M | $-61.9M | ||
| Q1 24 | $50.3M | $61.0M |
| Q4 25 | 41.6% | 50.6% | ||
| Q3 25 | 45.0% | -11.4% | ||
| Q2 25 | 47.1% | 8.6% | ||
| Q1 25 | 43.1% | -34.0% | ||
| Q4 24 | 44.2% | -6.4% | ||
| Q3 24 | 45.2% | -31.0% | ||
| Q2 24 | 42.4% | 3.5% | ||
| Q1 24 | 42.5% | 52.5% |
| Q4 25 | 32.9% | — | ||
| Q3 25 | 35.7% | -35.9% | ||
| Q2 25 | 36.8% | -15.4% | ||
| Q1 25 | 34.0% | -62.2% | ||
| Q4 24 | 34.7% | — | ||
| Q3 24 | 36.0% | -57.2% | ||
| Q2 24 | 32.9% | -83.9% | ||
| Q1 24 | 33.3% | 44.3% |
| Q4 25 | $1.75 | $0.32 | ||
| Q3 25 | $1.85 | $-0.16 | ||
| Q2 25 | $1.85 | $-0.06 | ||
| Q1 25 | $1.66 | $-0.21 | ||
| Q4 24 | $1.68 | $-0.14 | ||
| Q3 24 | $1.75 | $-0.15 | ||
| Q2 24 | $1.51 | $-0.33 | ||
| Q1 24 | $1.50 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $-302.0M |
| Total Assets | $14.8B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | — | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | $1.9B | $-302.0M | ||
| Q3 25 | $1.8B | $-451.4M | ||
| Q2 25 | $1.7B | $-433.5M | ||
| Q1 25 | $1.7B | $-426.2M | ||
| Q4 24 | $1.6B | $-388.7M | ||
| Q3 24 | $1.6B | $-370.2M | ||
| Q2 24 | $1.5B | $-344.2M | ||
| Q1 24 | $1.5B | $-294.3M |
| Q4 25 | $14.8B | $465.9M | ||
| Q3 25 | $14.2B | $364.0M | ||
| Q2 25 | $14.0B | $347.1M | ||
| Q1 25 | $14.0B | $324.0M | ||
| Q4 24 | $13.6B | $343.8M | ||
| Q3 24 | $13.3B | $314.1M | ||
| Q2 24 | $12.7B | $352.3M | ||
| Q1 24 | $12.6B | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $285.3M | $45.2M |
| Free Cash FlowOCF − Capex | $237.0M | — |
| FCF MarginFCF / Revenue | 130.9% | — |
| Capex IntensityCapex / Revenue | 26.7% | 0.0% |
| Cash ConversionOCF / Net Profit | 4.79× | — |
| TTM Free Cash FlowTrailing 4 quarters | $430.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.3M | $45.2M | ||
| Q3 25 | $75.4M | $-4.3M | ||
| Q2 25 | $78.1M | $-31.4M | ||
| Q1 25 | $77.0M | $-22.6M | ||
| Q4 24 | $261.2M | $-35.0M | ||
| Q3 24 | $77.6M | $-35.3M | ||
| Q2 24 | $100.2M | $-7.2M | ||
| Q1 24 | $66.3M | $53.8M |
| Q4 25 | $237.0M | — | ||
| Q3 25 | $63.7M | — | ||
| Q2 25 | $64.4M | — | ||
| Q1 25 | $65.6M | — | ||
| Q4 24 | $224.5M | — | ||
| Q3 24 | $72.4M | $-35.5M | ||
| Q2 24 | $94.1M | $-7.3M | ||
| Q1 24 | $56.1M | $53.8M |
| Q4 25 | 130.9% | — | ||
| Q3 25 | 36.3% | — | ||
| Q2 25 | 38.0% | — | ||
| Q1 25 | 39.8% | — | ||
| Q4 24 | 137.8% | — | ||
| Q3 24 | 44.2% | -68.7% | ||
| Q2 24 | 61.2% | -9.9% | ||
| Q1 24 | 37.1% | 39.0% |
| Q4 25 | 26.7% | 0.0% | ||
| Q3 25 | 6.7% | 0.0% | ||
| Q2 25 | 8.1% | 0.0% | ||
| Q1 25 | 6.9% | 0.0% | ||
| Q4 24 | 22.5% | 0.0% | ||
| Q3 24 | 3.2% | 0.3% | ||
| Q2 24 | 3.9% | 0.1% | ||
| Q1 24 | 6.8% | 0.1% |
| Q4 25 | 4.79× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | 4.62× | — | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.98× | — | ||
| Q1 24 | 1.32× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BANF
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
